RT Journal Article
SR Electronic
T1 90K/<em>LGALS3BP</em> Expression is Upregulated in COVID-19 but Does Not Restrict SARS-CoV-2 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.18.22277255
DO 10.1101/2022.07.18.22277255
A1 de Jarcy, Laure Bosquillon
A1 Akbil, Bengisu
A1 Leyens, Johanna
A1 Postmus, Dylan
A1 Harnisch, Greta
A1 Jansen, Jenny
A1 Schmidt, Marie L.
A1 Aigner, Annette
A1 Pott, Fabian
A1 Chua, Robert Lorenz
A1 Krist, Lilian
A1 Gentile, Roberta
A1 Mühlemann, Barbara
A1 Jones, Terry C.
A1 Niemeyer, Daniela
A1 Fricke, Julia
A1 Keil, Thomas
A1 Pischon, Tobias
A1 Janke, Jürgen
A1 Conrad, Christian
A1 Iacobelli, Stefano
A1 Drosten, Christian
A1 Corman, Victor M.
A1 Ralser, Markus
A1 Eils, Roland
A1 Kurth, Florian
A1 Sander, Leif
A1 Goffinet, Christine
YR 2022
UL http://medrxiv.org/content/early/2022/07/19/2022.07.18.22277255.abstract
AB Glycoprotein 90K, encoded by the interferon-stimulated gene LGALS3BP, displays broad antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate immune signaling. Here, we analyzed the expression of 90K/LGALS3BP in 44 hospitalized COVID-19 patients. 90K protein serum levels were significantly elevated in COVID-19 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC scRNA-seq datasets uncovered monocyte-specific induction of LGALS3BP mRNA expression in COVID-19 patients. In functional assays, neither 90K overexpression in susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-CoV-2 infection. Our data suggests that 90K/LGALS3BP contributes to the global type I IFN response during SARS-CoV-2 infection in vivo without displaying detectable antiviral properties.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) to C.G. (Collaborative Research Centre SFB900 Microbial Persistence and its Control, Project number 158989968, project C8) and funding of Berlin Institute of Health (BIH) to C.G. T.C.J. is partly funded by NIAID-NIH CEIRS contract HHSN272201400008C. This project was conducted with data from the German National Cohort (NAKO) (www.nako.de). NAKO is funded by the German Federal Ministry of Education and Research (BMBF, project funding reference numbers: 01ER1301A/B/C and 01ER1511D), federal states and the Helmholtz Association with additional financial support by the participating universities and the institutes of the Leibniz Association.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Charite Universitaetsmedizin Berlin gave ethical approval for this work (EA2/066/20). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. Codes for statistical analyses using linear mixed effects models will be available at https://github.com/GoffinetLab/SARS-CoV-2_90K_patient_study. https://github.com/GoffinetLab/SARS-CoV-2_90K_patient_study